America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research for the treatment of breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What types of cancers have shown effectiveness with AOH1996 based on current research?
**Interview with Dr. Linda Malkas on Targeted Chemotherapy Breakthrough**
*Editor:* Thank you for joining us today, Dr. Malkas. You’re a leading researcher at City of Hope Hospital, and you’ve contributed significantly to the development of a new cancer drug. Can you explain how this drug, AOH1996, works and what makes it unique?
*Dr. Malkas:* Thank you for having me. AOH1996 is a novel cell-killing drug designed for targeted chemotherapy. It works by attacking a mutated form of the PCNA protein, which plays a crucial role in DNA replication and tumor growth. By disrupting this protein, we essentially shut down the reproductive cycle of cancer cells, akin to how a blizzard can halt all flights at an airport.
*Editor:* That’s a fascinating analogy. What types of cancers has AOH1996 been shown to be effective against, and what does the research indicate so far?
*Dr. Malkas:* Our research indicates that AOH1996 has shown promising results against various cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We tested this molecule on over 70 cancer cell lines, and the results demonstrated that it selectively killed cancer cells while leaving healthy cells largely unharmed.
*Editor:* You mentioned clinical trials in humans as the next step. What timeline are you looking at for these trials, and what do you hope to achieve?
*Dr. Malkas:* We’re in the planning stages for human clinical trials and hope to initiate them within the next year or so. Our goal is to validate these findings in a clinical setting, assess the drug’s safety and efficacy, and ultimately bring this targeted treatment to patients who desperately need it.
*Editor:* It sounds like a significant step forward in cancer treatment. How do you envision the future of targeted therapies like AOH1996 impacting cancer care?
*Dr. Malkas:* I believe we are on the edge of a new era in oncology. Targeted therapies like AOH1996 could revolutionize the way we treat cancer by offering more personalized and effective treatment options with fewer side effects. The potential to selectively target cancer cells while sparing healthy ones is a game-changer in cancer therapy.
*Editor:* Thank you, Dr. Malkas, for sharing your insights with us. We look forward to following the progress of AOH1996 and its potential to change lives.
*Dr. Malkas:* Thank you for the opportunity to discuss our work!
